{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:03:50Z","timestamp":1771844630585,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.intimp.2005.11.016","type":"journal-article","created":{"date-parts":[[2005,12,22]],"date-time":"2005-12-22T08:30:20Z","timestamp":1135240220000},"page":"550-556","source":"Crossref","is-referenced-by-count":38,"title":["The role of high-dose immune globulin intravenous in the treatment of dermatomyositis"],"prefix":"10.1016","volume":"6","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2005.11.016_bib1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"New Engl J Med"},{"key":"10.1016\/j.intimp.2005.11.016_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2005.11.016_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00019052-200410000-00006","article-title":"Molecular studies in autoimmune inflammatory muscle disorders","volume":"17","author":"Dalakas","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.intimp.2005.11.016_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2003-41136","article-title":"Therapeutic approaches in patients with inflammatory myopathies","volume":"23","author":"Dalakas","year":"2003","journal-title":"Semin Neurol"},{"key":"10.1016\/j.intimp.2005.11.016_bib5","series-title":"Current therapy in neurology","first-page":"407","article-title":"The treatment of polymyositis, dermatomyositis, and inclusion body myositis","author":"Dalakas","year":"1996"},{"key":"10.1016\/j.intimp.2005.11.016_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00002281-198901040-00005","article-title":"Treatment of polymyositis and dermatomyositis","volume":"1","author":"Dalakas","year":"1989","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.intimp.2005.11.016_bib7","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2005.11.016_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.intimp.2005.11.016_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","article-title":"Treatment of dermatomyositis with intravenous immunoglobulin","volume":"91","author":"Lang","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.intimp.2005.11.016_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/jnnp.55.1.60","article-title":"High-dose intravenous human immunoglobulin in polymyositis resistant to treatment","volume":"55","author":"Jann","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.intimp.2005.11.016_bib11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","article-title":"Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin","volume":"43","author":"Soueidan","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2005.11.016_bib12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion body, myositis with IVIg: a double blind, placebo controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2005.11.016_bib13","first-page":"81","article-title":"Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies","volume":"151","author":"Illa","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.intimp.2005.11.016_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2005.11.016_bib15","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJM199405123301918","article-title":"Intravenous immune globulin for dermatomyositis","volume":"330","author":"Dalakas","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2005.11.016_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Down-regulation of TGF-\u03b21, mRNA, and protein in the muscle of patients with inflammatory myopathy after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2005.11.016_bib17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2005.11.016_bib18","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2005.11.016_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The role of IVIg in the treatment of autoimmune neurological disorders: evidence based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576905003127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576905003127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T07:26:30Z","timestamp":1547882790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576905003127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1567576905003127"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2005.11.016","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}